MedTrace Logo

Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring

NCT05994599 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-06-24

No results posted yet for this study

Summary

Single Dose Crossover Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (Delivering 0.015 mg/0.12 mg Per Day) Worn for 21 Days in Healthy Female Subjects

Conditions

  • Healthy Women
  • Female
  • Contraception

Interventions

COMBINATION_PRODUCT

EVE119 vaginal ring

EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day

COMBINATION_PRODUCT

Nuvaring vaginal ring

Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day

Sponsors & Collaborators

  • Evestra Inc.

    lead INDUSTRY

Principal Investigators

  • Ze'ev Shaked, PhD · Evestra CEO

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-29
Primary Completion
2023-12-11
Completion
2023-12-11
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05994599 on ClinicalTrials.gov